DEC 06, 2013
Two-year results from the RETAIN study presented at Retina Subspecialty Day show that treat-and-extend dosing is equivalent to prn dosing for diabetic macular edema.
RETAIN was a two-year randomized, controlled phase 3b study that included 372 patients with diabetic macular edema randomized to one of three treatment groups: ranibizumab administered according to a treat-and-extend protocol plus laser photocoagulation on day one, ranibizumab administered by treat-and-extend, and ranibizumab dosed prn.
In the treat-and-extend groups, patients were treated with monthly ranibizumab until BCVA remained stable for three months before treatment-free intervals were extended incrementally by one month, with a maximum treatment interval of three months.
If a decrease in BCVA was observed due to DME at a treat-and-extend visit, patients were again treated with monthly ranibizumab until BCVA remained stable for three monthly visits, before treatment was extended.
Investigators found that a treat-and-extend regimen offered a 40 percent decrease in patient visits, and that 70 percent of patients experienced a treatment-free interval of more than two months.